UBS AM
TARS icon

UBS AM’s Tarsus Pharmaceuticals TARS Stock Holding History

UBS AM’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.87M Sell
61,514
-1,192
-2% -$76.2K ﹤0.01% 1733
2026
Q1 		$4.4M Sell
62,706
-3,629
-5% -$254K ﹤0.01% 1624
2025
Q4 		$5.43M Buy
66,335
+3,732
+6% +$279K ﹤0.01% 1421
2025
Q3 		$3.72M Sell
62,603
-23,775
-28% -$1.17M ﹤0.01% 1507
2025
Q2 		$3.5M Buy
86,378
+15,158
+21% +$682K ﹤0.01% 1883
2025
Q1 		$3.66M Buy
71,220
+1,394
+2% +$68.9K ﹤0.01% 1720
2024
Q4 		$3.87M Buy
69,826
+10,991
+19% +$499K ﹤0.01% 1735
2024
Q3 		$1.94M Buy
58,835
+5,709
+11% +$160K ﹤0.01% 2055
2024
Q2 		$1.44M Buy
53,126
+30,406
+134% +$1.02M ﹤0.01% 2169
2024
Q1 		$826K Buy
+22,720
New +$668K ﹤0.01% 2101

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM's TARS Position: Q2 2026 in Review

UBS AM reduced its Tarsus Pharmaceuticals (TARS) stake by 1.9% in Q2 2026, selling an estimated $76.2K and leaving 61,514 shares worth $3.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

UBS AM first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.43M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • UBS AM held 61,514 shares of Tarsus Pharmaceuticals worth $3.87M as of Q2 2026.
  • UBS AM sold 1,192 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $76.2K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1733 holding.
  • UBS AM first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • UBS AM's Tarsus Pharmaceuticals position peaked at $5.43M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.